<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70513">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01927341</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2116</org_study_id>
    <secondary_id>2013-001986-18</secondary_id>
    <nct_id>NCT01927341</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors</brief_title>
  <official_title>A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Italy: National Institute of Health</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to
      assess the anti-tumor activity of MEK162 in combination with panitumumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicities in cycle 1 (Phase Ib)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Estimation of maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response rate (Phase II)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess clinical efficacy as per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequency and severity of AEs, SAEs, changes in laboratory values, vital signs, and electrocardiograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (Phase lb)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess preliminary anti-tumor activity as per RECIST 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free- survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>assess anti-tumor activity as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>assess anti-tumor activity as per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>assess anti-tumor activity as per RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>MEK162 + panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: Dose escalation. Phase II: 4 different patient populations: 1) patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy. 2) patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy. 3) patients with WT RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pretreated with EGFR tyrosine kinase inhibitor therapy. 4) patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>MEK162 plus panitumumab combination</description>
    <arm_group_label>MEK162 + panitumumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <arm_group_label>MEK162 + panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Metastatic colorectal cancer

          -  Progression on or following standard therapy, or no standard therapy (phase Ib).
             Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy
             regimens (phase II)

          -  Written documentation of mutant or wild-type RAS

          -  Life expectancy ≥ 3 months

          -  ECOG performance status ≤ 2

        Exclusion Criteria:

        Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other
        EGFR inhibitors

          -  Previous treatment with MEK-inhibitors

          -  History of severe infusion reactions to monoclonal antibodies.

          -  Symptomatic or untreated leptomeningeal disease

          -  Symptomatic brain metastasis

          -  Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as
             assessed by ophthalmologic examination at baseline that would be considered a risk
             factor for CSR/RVO and history of keratitis.

          -  Acute or chronic pancreatitis

          -  Clinically significant cardiac disease

          -  Not adequate hematologic, renal and hepatic function
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at Los Angeles Dept of Onc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Bishop</last_name>
      <phone>310-582-4069</phone>
      <email>rbishop@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev A. Wainberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Oncology Dept</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerry O'Neill</last_name>
      <phone>646-227-2129</phone>
      <email>oneillg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Rona B. Yeager</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEK162,</keyword>
  <keyword>panitumumab,</keyword>
  <keyword>mutant RAS,</keyword>
  <keyword>wild-type RAS,</keyword>
  <keyword>metastatic colorectal cancer,</keyword>
  <keyword>adult mCRC patient</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
